9M 2023 Financial Overview
H1 2023: R&D update
D1/D2 agonist: Potential new oral
treatment for Parkinson's disease
Innovative, orally available prodrug for a broad-acting dopamine
D₁/D2 receptor agonist providing continuous dopaminergic activation
25
Goals of the Lu AF28996 dopamine replacement therapy
Improved
efficacy
Improved
tolerability
Compared to
Compared to
D2 agonists
(OFF-time)
L-DOPA
(Dyskinesia)
1) Clinicaltrials.gov ID: NCT03565094 and NCT04291859. PD: Parkinson's disease
Improved
convenience
Compared to
D1/D2
apomorphine
(Pump)
Addressing Parkinson's disease
patients experiencing motor
complications
•
•
Small molecule with agonistic properties
towards dopamine D1 and D2 receptors
Oral symptomatic treatment for PD patients
experiencing motor complications
•
Clinical phase I studies¹)
•
Single- and sequential-ascending-dose of '996
in healthy young men
Open-label study investigating the safety,
tolerability and pharmacokinetic profile of '996
in patients with Parkinson's disease
Phase lb concluding with phase II start
planned in 2024View entire presentation